Evolus (EOLS) Investor Day 2024 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2024 summary
20 Jan, 2026Strategic vision and market positioning
Transitioning from medical aesthetics/pharma to a broader beauty focus, targeting millennials and the $1.5T beauty and wellness market, with a design-centric, digital-first approach.
Defined a new 'performance beauty' category, emphasizing high-quality, data-backed products and deep consumer understanding.
Achieved 13% U.S. market share in five years, with Jeuveau as the fastest-growing brand and second-highest awareness in its category.
Expanding global reach into seven key markets, aiming for $100M in international revenue by 2028.
Cash pay model, co-branded media, and digital platforms drive unique value for providers and consumers.
Product innovation and clinical differentiation
Jeuveau and Evolysse fillers supported by clinical data showing non-inferiority or superiority to market leaders, with high patient satisfaction and natural results.
Evolysse uses Cold Technology for more natural, stress-resistant HA gels, with launches sequenced through 2027.
Filler portfolio (Form, Smooth, Sculpt, Lips) covers 95% of HA procedures, with staged launches and additional indications planned.
Heavy investment in medical education, including Evolus Academy to double training reach.
Digital platforms and loyalty programs (Evolus Rewards, Club Evolus) drive patient retention and practice growth.
Digital platform and customer engagement
Proprietary digital platform enables seamless ordering, practice management, and patient loyalty, with over 2.2M app logins and 16,000 unique users.
Co-branded media delivers hyper-local, customized campaigns, driving 1.5B impressions and national brand awareness.
Evolus Rewards and Club Evolus have nearly 1M enrolled consumers, supporting high patient retention and repeat business.
Club Evolus offers quarterly treatments for a monthly fee, increasing patient frequency and unit usage.
Digital infrastructure is scalable for new products and international markets, supporting efficient growth.
Latest events from Evolus
- Double-digit growth, expanding HA portfolio, and Sculpt approval set the stage for 2026-2028.EOLS
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - Low-cost, quality-driven cannabis operator targets rapid, profitable multi-state growth.EOLS
Investor presentation10 Apr 2026 - Portfolio expansion and market recovery drive double-digit growth outlook through 2028.EOLS
Leerink Global Healthcare Conference 202611 Mar 2026 - 2025 saw double-digit growth and Q4 profitability; 2026 outlook targets margin expansion and sustained growth.EOLS
Q4 20253 Mar 2026 - Record Q2 revenue and first non-GAAP profit drive raised 2024 guidance and global growth targets.EOLS
Q2 20242 Feb 2026 - Achieved early profitability, expanding with new fillers and strong millennial-driven growth.EOLS
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase2 Feb 2026 - Q3 revenue up 22% to $61.1M; EU Estyme/Evolysse approval; 2024 guidance $260M–$266M.EOLS
Q3 202416 Jan 2026 - Innovative aesthetics firm targets $700M+ revenue by 2028, driven by new fillers and digital strategy.EOLS
Stifel 2024 Healthcare Conference13 Jan 2026 - New HA filler launch and strong growth set the stage for $700M+ revenue by 2028.EOLS
Barclays 27th Annual Global Healthcare Conference26 Dec 2025